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Introduction: Real-world evidence of the effectiveness of pharmacological thromboprophylaxis for venous
thromboembolism (VTE) is limited. Our objective was to assess the effectiveness and safety of thromboprophylactic
regimens in Japanese patients undergoing joint replacement in a real-world setting.
Method: Overall, 1,294 patients (1,073 females and 221 males) who underwent total knee arthroplasty (TKA) and 868
patients (740 females and 128 males) who underwent total hip arthroplasty (THA) in 34 Japanese national hospital
organization (NHO) hospitals were enrolled. The primary efficacy outcome was the incidence of deep vein thrombosis
(DVT) detected by mandatory bilateral ultrasonography up to post-operative day (POD) 10 and pulmonary embolism
(PE) up to POD28. The main safety outcomes were bleeding (major or minor) and death from any cause up to POD28.
Results: Patients undergoing TKA (n = 1,294) received fondaparinux (n = 360), enoxaparin (n = 223), unfractionated
heparin (n = 72), anti-platelet agents (n = 45), or no medication (n = 594). Patients undergoing THA (n = 868)
received fondaparinux (n = 261), enoxaparin (n = 148), unfractionated heparin (n = 32), anti-platelet agents (n = 44), or
no medication (n = 383). The incidence rates of sonographically diagnosed DVTs up to POD10 were 24.3% in
patients undergoing TKA and 12.6% in patients undergoing THA, and the incidence rates of major bleeding up to
POD28 were 1.2% and 2.3%, respectively. Neither fatal bleeding nor fatal pulmonary embolism occurred. Significant risk
factors for postoperative VTE identified by multivariate analysis included gender (female) in both TKA and THA groups
and use of a foot pump in the TKA group. Only prophylaxis with fondaparinux reduced the occurrence of VTE
significantly in both groups. Propensity score matching analysis (fondaparinux versus enoxaparin) showed that the
incidence of DVT was lower (relative risk 0.70, 95% confidence interval (CI) 0.58 to 0.85, P = 0.002 in TKA and relative risk
0.73, 95% CI 0.53 to 0.99, P = 0.134 in THA) but that the incidence of major bleeding was higher in the fondaparinux
than in the enoxaparin group (3.4% versus 0.5%, P = 0.062 in TKA and 4.9% versus 0%, P = 0.022 in THA).
Conclusions: These findings indicate that prophylaxis with fondaparinux, not enoxaparin, reduces the risk of DVT but
increases bleeding tendency in patients undergoing TKA and THA.
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Postoperative venous thromboembolism (VTE), consisting
of deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a major life-threating complication in patients
undergoing surgery [1]. Patients undergoing total hip
and knee arthroplasty (THA and TKA, respectively)
are at high risk of VTE [2]. In patients undergoing THA
or TKA, thromboprophylaxis with low-molecular-weight
heparin (LMWH) or factor Xa inhibitors is recommended
for a minimum of 10 to 14 days up to 35 days in current
evidence-based guidelines [3,4]. However, it is not clear
whether these regimens affect important patient outcomes
in “real-world” settings [5]. Despite the need for effective
and safe thromboprophylactic drugs in patients under-
going joint replacement therapy, few real-world data
assessed the benefits of anticoagulants in this population.
The translation of evidence-based guidelines into everyday
clinical practice is not immediate [6]. Adoption of these
recommendations in patients undergoing elective ortho-
pedic surgery depends on combinations of patient-associ-
ated factors, including age, gender, and comorbidities, and
physician-associated factors, including clinical practice
and institutional compliance, as well as the widespread
dissemination of guidelines and educational initiatives
to reinforce published guidelines [7,8]. Clinical trials in
highly selected patients must be supplemented by efficacy
and safety data in “real-world” settings. These evidence
gaps have led to differences among recent recommenda-
tions; although these guidelines recommend thrombopro-
phylaxis after joint replacement, their choices of optimal
prophylactic agents differ [9,10].
In Japan, fondaparinux (June 2007) and enoxaparin
(April 2008) had been approved for thromboprophylaxis
in patients undergoing THA, TKA, or hip fracture surgery
[11,12]. Although these agents are widely used throughout
Japan, their effectiveness remains unclear. The Japanese
study of Prevention and Actual situation of Venous
Thromboembolism after Total Arthroplasty (J-PSVT) is a
nationwide multicenter cohort study designed to gain
insights into the effectiveness (that is, the prevention of
VTE) and safety (that is, the incidence of bleeding and
other adverse events) of the “real-world” prophylaxis
of VTE after joint replacement surgery in 34 Japanese
National Hospital Organization (NHO) hospitals. The
main objective of this study was to determine practice
patterns of VTE prophylaxis and their outcomes, includ-
ing symptomatic and non-symptomatic VTEs, bleeding
events, and all-cause mortality, in Japanese patients under-
going total joint replacement.
Materials and methods
Study design
The J-PSVT is a hospital-based, prospective cohort study
designed to document the effectiveness and safety ofcurrent standard thromboprophylactic agents, including
unfractionated heparin, LMWH, fondaparinux, and anti-
platelet agents, approved for use in Japan. Data were
collected prospectively on all patients undergoing pri-
mary TKA and THA in 34 NHO hospitals since 2007 to
2010. The primary aim of the J-PSVT was to determine
the rates of VTEs in patients undergoing TKA and
THA, and all patients were evaluated for the presence of
all (symptomatic/non-symptomatic) DVT on postoperative
day 10 (POD10). Data on patient demographics, primary
diagnosis, pre-existing comorbid conditions, length of
operation, type of anesthesia, VTE prophylaxis (including
type and duration), and mechanical VTE prophylaxis were
gathered by using standard case report forms. The trial
was registered in the Japan UMIN Clinical Trial Registry
(UMIN000001366). The study protocol was approved
by the ethics committees of the National Hospital
Organization central institutional review board (#0623004).
Written informed consent was obtained from each indi-
vidual for their clinical records to be used in this study.
Patient enrollment
Patients who were at least 20 years old were eligible if
they were scheduled for knee or hip replacement surgery
for primary joint diseases, such as osteoarthritis and
rheumatoid arthritis. Patients were excluded if they had
(1) a predefined risk factor for bleeding (for example,
gastrointestinal ulcer and hemorrhagic stroke), (2) a
coagulation disorder, (3) heart failure (New York Heart
Association class III or IV), (4) renal impairment (cre-
atinine clearance rate of less than 30 mL/min), or (5)
liver dysfunction: aspartate transaminase (AST) or alanine
transaminase (ALT) of at least five times the upper limit
of normal or total bilirubin of at least two times the upper
limit of normal. Patients were also excluded if they had
undergone joint replacement within 3 months prior to
hospital admission, were scheduled to undergo bilateral
joint replacement, were unable to walk, or had any
severe illness.
Outcome measures
There were two primary effectiveness outcomes: the com-
posite incidence of asymptomatic/symptomatic DVT up
to POD10 and the incidence of fatal/non-fatal PE up to
POD28. All enrolled patients were assessed for DVT on
POD10, or earlier if thrombosis was clinically suspected,
by standard Doppler ultrasonography. DVT diagnosis re-
quired confirmation of the presence of a venous thrombus
by compression ultrasonography (CUS) [13] performed by
using a standardized method [14-16]. All sonographers
were adequately trained. Just before the start of study, the
participating sonographers received detailed instructions
for standardized procedures in a specially organized con-
ference and required a certification process. All patients
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who were unaware of both risk factors and thrombopro-
phylaxis. The minimal requirement for B-mode ultra-
sonography was a high-resolution real-time scanner
equipped with a 5-MHz electronically focused linear-
array transducer, although an ultrasonography device
with better specifications (including Doppler and color-
Doppler options) was allowed. If Doppler or color-Doppler
techniques were used, it was critical that the B-mode
pictures allowed the vein walls to be clearly identified.
The single criterion indicating the presence of a venous
thrombosis was failure to fully compress the venous
lumen despite firm compression with the transducer
probe. DVT was classified as being in either a proximal
(that is, the popliteal vein or any vein proximal to it) or
a distal (that is, any vein distal to the popliteal vein)
vein. A pulmonary embolism was defined as definite if
computed tomography/angiography of the chest or ven-
tilation-perfusion scintigraphy showed a characteristic
intraluminal filling defect. The primary safety outcomes
were the incidences of major bleeding and death from all
causes up to POD28. Major bleeding was defined as
hemorrhage occurring at a critical site (for example, intra-
cranial hemorrhage), resulting in the need for a major
therapeutic intervention (for example, surgery), causing
hemodynamic compromise, requiring at least one unit of
red-cell concentrates, or resulting in death. Minor bleed-
ing was defined as bleeding that did not fulfill the criteria
for major bleeding.
Data collection
Data from all participating doctors were entered into the
J-PSVT database at the data center of the NHO head-
quarters Center for Support and Education of Clinical
Research via the HospNet internet system. Previous co-
morbid conditions of each patient were reviewed by each
of the principal physicians. These conditions included
cancer, stroke, chronic kidney disease, diabetes, hyperlip-
idemia, arrhythmia, and cardiovascular diseases as well
as previous thrombosis. Medical information collected
during follow-up included the development of cardio-
vascular events, including DVT, myocardial infarction,
pulmonary embolism, heart failure, arrhythmia, and cere-
brovascular accident as well as gastrointestinal bleeding
and death.
Statistical analysis
Discrete variables were compared by using chi-squared
tests and continuous variables by using Kruskal-Wallis
rank tests. Multiple logistic regression analysis was used
to estimate the risk factors independently associated
with the primary composite outcome: asymptomatic/
symptomatic DVT up to POD10 and PE up to POD28.
Age, sex, history of venous thrombosis, epidermalgrowth factor receptor (less than 60 mL/min per 1.73 m2
versus at least 60 mL/min per 1.73 m2), body mass index
(at least 30 kg/m2 versus less than 30 kg/m2), anesthesia
(general versus others), operation time (at least 120 mi-
nutes versus less than 120 minutes), foot pump use (yes
versus no), elastic stocking use (yes versus no), and dif-
ferent anti-coagulating agents (none versus unfractio-
nated heparin (UFH), enoxaparin, fondaparinux, and
other agents) were treated as independent variables.
Multivariate logistic regression was used to calculate odds
ratios and 95% confidence intervals (CIs) after controlling
simultaneously for potential confounders. Individuals with
missing data were excluded from the model.
Propensity score matching [17] was performed to
minimize any effects of confounding caused by non-
randomized assignment to VTE prophylaxis. Propensity
score matching is used to reduce the impact of selection
bias and allows relevant variables to be balanced in
patients treated with fondaparinux or enoxaparin for
VTE prophylaxis. Logistic regression was used to estimate
a propensity score, representing the risk for VTE. Propen-
sity scores were matched 1:1 in patients taking fondapari-
nux and enoxaparin to compare patients at equivalent
risks for VTE. After matching, we compared the incidence
of the primary outcome and major bleeding events after
surgery. The ratio of risk in the fondaparinux compared
with the enoxaparin was calculated by using chi-squared
tests. All reported P values were two-tailed. All data pro-
cessing and analysis were performed by using the Statis-
tical Analysis System (SAS) and SPSS version 18 software
(SPSS, Chicago, IL, USA).
Results
Study populations and treatments
Between 1 July 2007 and 31 May 2010, 2,211 patients
undergoing THA or TKA at 34 NHO hospitals were
screened for eligibility. Of these, 25 patients were exclu-
ded: 17 with exclusion criteria and 8 who cancelled sur-
gery. Of the 2,186 enrolled patients, 1,307 underwent
TKA and 879 patients underwent THA. Primary effective-
ness outcome was not assessed in 13 patients who under-
went TKA and in 11 who underwent THA owing to the
lack of ultrasonography or inadequate medical treatments.
Thus, the overall study population consisted of 1,294
patients who underwent TKA and 868 patients who
underwent THA (Figure 1).
The demographic and clinical characteristics of these
patients are shown in Table 1. VTE prophylaxis showed
apparent variations. Most physicians in Japan prescribe
more than one modality (mechanical and pharmacological)
in combination, with foot pumps and elastic stockings used
in combination with pharmacological prophylaxis in many
of these patients. Pharmacological thromboprophylaxis in
patients undergoing TKA consisted of fondaparinux in 360
Figure 1 Flow diagram of patient enrollment.
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(5.6%), and anti-platelet agents (others: aspirin 41, ticlopi-
dine 2, and cilostazol 2) in 45 (3.5%), whereas 594 patients
(45.9%) received no medication. Among these 594 patients
without medication, 591 patients (99.5%) received mechan-
ical thromboprophylaxis (elastic stocking 36.5%, foot pump
15.0%, and elastic stocking plus foot pump 48.0%). These
devices were initiated post-operatively, and the same type
of elastic stockings were used in both patients receiving
TKA and THA. Among patients undergoing THA, 261
(30.1%) were treated with fondaparinux, 148 (17.1%)
with enoxaparin, 32 with UFH (3.7%) anti-platelet agents
(others: aspirin 42 and cilostazol 2) in 44 (5.1%), and 383
(44.1%) with no medication. Among 383 patients without
medication, 381 patients (99.5%) received mechanical
thromboprophylaxis (elastic stocking 40.2%, foot pump
7.8%, and elastic stocking plus foot pump 51.4%). Patients
weighing less than 50 kg and at least 50 kg received once-
daily subcutaneous injection of 1.5 and 2.5 mg fondapari-
nux, respectively, or twice-daily subcutaneous injections
of 2,000 international units (IU) of enoxaparin sodium
(Clexane, Sanofi, Paris, France). Fondaparinux was initi-
ated after 24 hours from wound closure, and enoxaparin
after 24 to 36 hours. UFH was initiated after 6 to 12 hours
from wound closure. The mean doses (lengths) of throm-
boprophylaxis with fondaparinux, enoxaparin, and UFH
were 1.7 ± 0.5 mg (10.2 ± 7.2 days), 2,854 ± 992 IU (8.1 ±
4.4 days), and 13,911 ± 101 units (5.8 ± 5.8 days), re-
spectively, in patients undergoing TKA and 1.8 ± 0.5 mg
(9.5 ± 4.0 days), 3,635 ± 775 IU (8.4 ± 3.9 days), and10,133 ± 2,162 units (5.1 ± 3.0 days), respectively, in
patients undergoing THA. Treatment with anti-platelet
agents before the day of surgery was considered a conti-
nuation of thromboprophylaxis, and these patients were
excluded (inadequate medical treatment).
Incidence of VTE and major bleeding
No mortality was confirmed in this study. Three events of
cardiovascular disease (cerebral infarction) were observed
during the follow-up periods (up to POD28).
The incidence of the composite of symptomatic and
non-symptomatic DVT differed in patients undergoing
TKA and THA. The overall rate of DVT through POD10
in patients undergoing TKA (Table 2) was 24.3% (314
patients), and symptomatic DVT occurred in 12 patients
(0.9%). PEs were confirmed in one patient treated with
fondaparinux (day 7) and in one patient with no medi-
cation (day 13). In patients undergoing THA (Table 3),
the overall rate of DVT up to POD10 was 12.6% (109 pa-
tients), and symptomatic DVT occurred in two patients
(0.2%) and none experienced PE. Symptomatic DVT over
the POD10 and within POD28 was found in two patients
undergoing TKA and one patient undergoing THA.
DVT rates varied among patients receiving different pat-
terns of pharmacologic thromboprophylaxis. The overall
rates of DVT up to POD10 in patients undergoing TKA
were 16.7% with fondaparinux, 26.5% with enoxaparin,
33.3% with UFH, 26.7% with other medications, and
26.6% with no medication (Table 2). The overall rates of
DVT up to POD10 in patients undergoing THA were
Table 1 Baseline and other characteristics of the study
patients
TKA (n = 1,294) THA (n = 868)
Gender, male/female 221/1,073 128/740
Age, years
Mean ± SD 73.9 ± 8.0 66.7 ± 10.5
Range 34-93 23-94
Weight, kg
Mean ± SD 57.8 ± 10.6 54.8 ± 11.4
Body mass index, kg/m2
Mean ± SD 25.4 ± 3.9 23.6 ± 4.2
Range 14.5-44.0 14.2-56.4
History of venous thrombolism, n (%) 16 (1.2%) 5 (0.6%)
Comorbidities, n (%)
Hypertension 706 (54.6%) 307 (35.4%)
Ischemic heart disease 75 (5.8%) 40 (4.6%)
Diabetes 194 (15.0%) 69 (7.9%)
Cerebrovascular disease 63 (4.9%) 24 (2.8%)
Operation time, minutes
Mean ± SD 127 ± 37.2 123.3 ± 43.0
Range 42-400 35-332
Type of anesthesia, n (%)
General 366 (28.3%) 280 (32.3%)
Epidural 56 (4.3%) 31 (3.6%)
Spinal 337 (26.0%) 88 (10.1%)
General + epidural 535 (41.3%) 469 (54.0%)
Primary diseases, n (%)
Rheumatoid arthritis 204 (15.8%) 52 (6.0%)
Osteoarthritis 1,084 (83.8%) 751 (86.5%)
Others 6 (0.5%) 65 (7.5%)
Use of elastic stocking, n (%) 1,095 (84.6%) 792 (91.2%)
Use of foot pump, n (%) 939 (72.6%) 669 (77.1%)
Use of tourniquet, n (%) 1,244 (96.1%) -
Use of cement, n (%) 1,208 (93.4%) 183 (21.1%)
Prophylaxis
Unfractionated heparin, n (%) 72 (5.6%) 32 (3.7%)
Enoxaparin, n (%) 223 (17.2%) 148 (17.1%)
Fondaparinux, n (%) 360 (27.8%) 261 (30.1%)
Others, n (%) 45 (3.5%) 44 (5.1%)
No medication, n (%) 594 (45.9%) 383 (44.1%)
Laboratory data
Serum albumin, g/dL
Mean ± SD 4.1 ± 0.4 4.1 ± 0.4
Hemoglobin, g/dL
Mean ± SD 12.4 ± 1.6 12.1 ± 1.5
Platelet count, 104/μL
Table 1 Baseline and other characteristics of the study
patients (Continued)
Mean ± SD 24.5 ± 14.3 26.4 ± 11.1
e-GFR, mL/min per 1.73 m2
Mean ± SD 73.4 ± 21.4 80.8 ± 20.1
e-GFR, estimated glomerular filtrating ratio; SD, standard deviation; THA, total
hip arthroplasty; TKA, total knee arthroplasty.
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with UFH, 18.2% with other medications, and 16.2% with
no medication (Table 3). Safety analysis showed that the
incidences of major bleeding up to POD28 in patients
undergoing TKA and THA were 1.2% (n = 15) and 2.3%
(n = 20), respectively. Major or minor bleeding occurred at
early periods postoperatively in both patients receiving
TKA (major 2.7 ± 3.5 days, minor 5.0 ± 2.7 days) and
THA (major 2.6 ± 2.9 days, minor 5.6 ± 3.0 days). Major
bleeding was also confirmed in patients without pharmaco-
logic thromboprophylaxis (TKA 5 patients 33.3%, THA 7
patients 35.0%). No fatal bleeding was observed (Table 4).
Risk factors for postoperative DVT
Univariate analysis isolated several variables which are
significantly different between patients with or without the
primary effectiveness outcomes (Tables 5 and 6). Multi-
variate analyses were performed to identify independent
predictors of the primary effectiveness outcomes (Tables 5
and 6). Increased VTE rates were significantly associated
with female gender and the use of foot pumps in patients
undergoing TKA (Table 7) and with female gender and
older age in patients undergoing THA (Table 8). The
use of general anesthesia was significantly associated
with reduced risks of VTE in both groups. Among phar-
macological prophylaxis, only prophylaxis with fondapari-
nux was significantly associated with reduced risks of
VTE in both groups.
Effectiveness and safety of fondaparinux versus
enoxaparin in propensity score-matched analysis
To date, no randomized controlled trial has directly com-
pared fondaparinux and enoxaparin for thromboprophy-
laxis in Japanese patients. We therefore used propensity
score matching to adjust for differences in baseline risks
to patients treated with these agents. We matched equal
numbers of patients receiving fondaparinux and eno-
xaparin, with no significant between group differences,
except for the rates of general anesthesia (TKA), the use
of foot pump (TKA), and serum albumin concentrations
(TKA and THA), in baseline characteristics (Tables 9
and 10). Tables 11 and 12 show the overall rates of DVT
and major bleeding in the propensity score-matched pa-
tients undergoing TKA (Table 11) and THA (Table 12).
The incidence of any DVT up to POD10 was lower with
fondaparinux than with enoxaparin, both in patients
Table 2 Incidences of primary effectiveness outcomes in patients receiving TKA
Fondaparinux Enoxaparin UFH Others Medication (−) Total
n = 360 (%) n = 223 (%) n = 72 (%) n = 45 (%) n = 594 (%) n = 1,294 (%)
All venous thromboembolism 61 (16.9) 59 (26.5) 24 (33.3) 12 (26.7) 158 (26.6) 314 (24.3)
Any DVT (up to POD10 ) 60 (16.7) 59 (26.5) 24 (33.3) 12 (26.7) 158 (26.6) 314 (24.3)
Symptomatic DVT 2 (0.6) 3 (1.3) 0 1 (2.2) 6 (1.0) 12 (0.9)
Distal 1 (0.3) 2 (0.9) 0 1 (2.2) 4 (0.7) 8 (0.6)
Proximal 1 (0.3) 1 (0.4) 0 0 2 (0.3) 4 (0.3)
Non-symptomatic DVT 59 (16.4) 56 (25.1) 24 (33.3) 11 (24.4) 152 (25.6) 302 (23.3)
Distal 51 (14.2) 52 (23.3) 21 (29.2) 11 (24.4) 133 (22.4) 268 (20.7)
Proximal 8 (2.2) 4 (1.8) 3 (4.2) 0 19 (3.2) 34 (2.6)
PE (up to POD28) 1 (0.3) 0 0 0 1 (0.2) 2 (0.2)
CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; POD, post-operative day; TKA, total knee arthroplasty; UFH, unfractionated heparin.
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versus 11.1%). However, the rate of major bleeding events
was higher in fondaparinux- than in enoxaparin-treated
patients in both groups.
Discussion
Patients undergoing joint replacement surgery require
effective thromboprophylaxis with both pharmaceutical
agents and mechanical methods [3,4]. Despite these
measures, however, approximately 10% to 15% of patients
experience subclinical DVT after surgery, and 0.5% to
2.0% have symptomatic VTE during the first 3 months
after surgery [18,19]. Thromboprophylactic agents appro-
ved in Japan include enoxaparin, fondaparinux [11,12],
and the oral factor Xa inhibitor edoxaban, which was
approved after the start of this study [20], all of which are
clinically used in real-world settings [21]. Translating the
efficacy and safety of an agent from a clinical trial to real-
world practice is often challenging because participants in
trials are usually younger and have less medically complex
illnesses. Because the risks of both thrombosis and
hemorrhage increase substantially with age and with theTable 3 Incidences of primary effectiveness outcomes in patie
Fondaparinux Enoxaparin
n = 261 (%) n = 148 (%)
All venous thromboembolism 17 (6.5) 17 (11.5)
Any DVT (up to POD10 ) 17 (6.5) 17 (11.5)
Symptomatic DVT 0 1 (0.7)
Distal 0 1 (0.7)
Proximal 0 0
Non-symptomatic DVT 17 (6.5) 16 (10.8)
Distal 15 (5.7) 13 (8.8)
Proximal 2 (0.8) 3 (2.0)
PE (up to POD28) 0 0
CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; POD,burden of chronic diseases, the effectiveness of newly
approved agents in real-world settings should be carefully
monitored, particularly among older patients [22].
We have assessed the rates of symptomatic/non-symp-
tomatic VTEs and bleeding in a real-world setting of
patients undergoing TKA and THA while receiving vari-
ous thromboprophylactic regimens. We found that the
overall rates of asymptomatic and symptomatic DVT up
to POD10 and PE up to POD28 were 23.3%, 0.9%, and
0.2%, respectively, in patients undergoing TKA and 12.3%,
0.2%, and 0%, respectively, in patients undergoing THA.
Pharmacological prophylaxis was administered to 54%
of patients undergoing TKA and 56% undergoing THA.
However, multivariate analysis showed that treatment
with fondaparinux, but not enoxaparin, reduced VTE
(up to POD10). In addition, multivariate analysis showed
that risk factors for postoperative VTE included older age
(more than 75 years) and female gender, both of which
were previously shown to be risk factors for VTEs [23].
We also found that intermittent plantar compression (foot
pumps) was an independent risk factor for VTE in pa-
tients undergoing TKA, a finding not previously shown.nts receiving THA
UFH Others Medication (−) Total
n = 32 (%) n = 44 (%) n = 383 (%) n = 868 (%)
5 (15.6) 8 (18.2) 62 (16.2) 109 (12.6)
5 (15.6) 8 (18.2) 62 (16.2) 109 (12.6)
0 0 1 (0.3) 2 (0.2)
0 0 1 (0.3) 2 (0.2)
0 0 0 0
5 (15.6) 8 (18.2) 61 (15.9) 107 (12.3)
3 (9.4) 8 (18.2) 51 (13.3) 90 (10.4)
2 (6.3) 0 10 (2.6) 17 (2.0)
0 0 0 0
post-operative day; THA, total hip arthroplasty; UFH, unfractionated heparin.
Table 4 Incidences of bleeding in patients receiving joint replacement
TKA THA
n = 1,294 (%) n = 868 (%)
All bleeding events, n (%) 46/1,294 (3.6) 31/868 (3.6)
Major bleeding 15/1,294 (1.2) 20/868 (2.3)
Bleeding in critical organ 1/1,294 (0.1) 0/868 (0)
Bleeding leading to reoperation 0/1,294 (0) 0/868 (0)
Bleeding requiring of ≧1 unit of transfusion 14/1,294 (1.1) 20/868 (2.3)
Bleeding contributing to death 0/1,294 (0) 0/868 (0)
Minor bleeding 31/1,294 (2.4) 11/868 (1.3)
THA, total hip arthroplasty; TKA, total knee arthroplasty.
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propensity score-matched fondaparinux- and enxoparin-
treated groups, we found that, compared with enoxaparin,
fondaparinux reduced the risk of DVT but increased the
risk of major bleeding.
Adherence to treatment guidelines can vary by country
and clinical practice. A recent publication by the Global
Orthopedic Registry (GLORY) reported that only 62%
and 69% of patients undergoing THR and TKR, respect-
ively, complied with American College of Chest Physicians
guidelines [24]. In comparison, 56% and 54% of patients
in our J-PSVT registry who underwent THA and TKA,
respectively, received pharmacological thromboprophy-
laxis. A recent meta-analysis of symptomatic VTE rates
prior to hospital discharge, in patients receiving thrombo-
prophylaxis with fondaparinux, LMWH, or oral Xa inhibi-
tors for TKA and THA, found that the VTE rates inTable 5 Baseline characteristics of patients with or
without DVT in patients receiving TKA
DVT (+) DVT (−) P value
n = 314 n = 980
Age, ≧75 years 185 (58.9%) 512 (52.2%) 0.039
Female gender 274 (87.3%) 799 (81.5%) 0.019
History of venous thrombosis 6 (1.9%) 10 (1.0%) 0.169
e-GFR, <60 mL/min per 1.73 m2 86 (27.5%) 245 (25.1%) 0.392
Body mass index, ≧30 kg/m2 31 (9.9%) 118 (12.1%) 0.287
General anesthesia 199 (63.4%) 702 (71.6%) 0.006
Use of tourniquet 308 (98.1%) 936 (95.5%) 0.039
Operation time, ≧120 minutes 167 (53.2%) 562 (57.3%) 0.196
Use of foot pump 241 (76.8%) 698 (71.2%) 0.056
Use of elastic stocking 267 (85.0%) 828 (84.5%) 0.817
Medications
Unfractionated heparin 24 (7.6%) 48 (4.9%) 0.065
Enoxaparin 59 (18.8%) 164 (16.7%) 0.401
Fondaparinux 61 (19.4%) 299 (30.5%) <0.0001
Others 12 (3.8%) 33 (3.4%) 0.702
CI, confidence interval; DVT, deep vein thrombosis; e-GFR, estimated glomerular
filtrating ratio; PE, pulmonary embolism; TKA, total knee arthroplasty.patients undergoing TKA and THA were 1.09% and
0.53%, respectively [25]. We found that the rates of overall
and symptomatic DVT were lower in patients undergoing
TKA (24.3% and 0.9%, respectively) and in patients under-
going THA (12.6% and 0.2%, respectively). Interpretation
of DVT rate in patients who underwent orthopedic
surgery may be affected by differences in time frames,
methods of diagnosing DVT, and thromboprophylaxis
protocol. Additionally, risk factors for VTE in Asian
patients may not be different from those of Western pa-
tients through the genetic backgrounds. Deficiencies of
the natural anti-coagulants (protein C, protein S, and anti-
thrombin) are the predominant thrombophilias in Asia,
whereas factor V Leiden and prothrombin G20210A gene
mutation are rarely reported [26].
We found that intermittent plantar compression (foot
pumps) was an independent risk factor for VTE in pa-
tients undergoing TKA, a result not previously reported.
Mechanical prophylaxis, both pneumatic compressionTable 6 Baseline characteristics of patients with or
without DVT in patients receiving THA
DVT(+) DVT(−) P value
n = 109 n = 759
Age, ≧75 years 43 (39.4%) 189 (24.9%) 0.001
Female gender 102 (93.6%) 638 (84.1%) 0.009
e-GFR, <60 mL/min per 1.73 m2 17 (15.6%) 102 (13.5%) 0.547
Body mass index, ≧30 kg/m2 7 (6.4%) 49 (6.5%) 0.981
General anesthesia 83 (76.1%) 666 (87.7%) 0.001
Operation time, ≧120 minutes 42 (38.5%) 353 (46.5%) 0.118
Use of foot pump 83 (76.1%) 586 (77.2%) 0.806
Use of elastic stocking 95 (87.2%) 697 (91.8%) 0.106
Medications
Unfractionated heparin 5 (4.6%) 27 (3.6%) 0.374
Enoxaparin 17 (15.6%) 131 (17.3%) 0.666
Fondaparinux 17 (15.6%) 244 (32.1%) <0.0001
Others 8 (7.3%) 36 (4.7%) 0.248
CI, confidence interval; DVT, deep vein thrombosis; e-GFR, estimated glomerular
filtrating ratio; PE, pulmonary embolism; THA, total hip arthroplasty.
Table 7 Multivariate logistic regression for the composite
effectiveness outcomes (symptomatic/non-symptomatic DVT
up to POD10 and PE up to POD28) in patients receiving TKA
Predictors Odds ratio 95% CI P value
Age, ≧75 years 1.30 0.99-1.71 0.060
Female gender 1.58 1.08-2.31 0.018
History of venous thrombosis 1.11 0.36-3.46 0.846
e-GFR, <60 mL/min per 1.73 m2 1.05 0.77-1.42 0.768
Body mass index, ≧30 kg/m2 0.90 0.58-1.38 0.626
General anesthesia 0.60 0.45-0.80 0.001
Use of tourniquet 2.31 0.95-5.59 0.065
Operation time, ≧120 minutes 0.91 0.69-1.21 0.504
Use of foot pump 1.60 1.15-2.21 0.005
Use of elastic stocking 1.28 0.85-1.94 0.234
Medications
Unfractionated heparin 1.61 0.92-2.79 0.093
Enoxaparin 1.01 0.71-1.45 0.961
Fondaparinux 0.51 0.36-0.72 0.000
Others 1.00 0.49-2.02 0.992
CI, confidence interval; DVT, deep vein thrombosis; e-GFR, estimated glomerular
filtrating ratio; PE, pulmonary embolism; TKA, total knee arthroplasty.
Table 9 Baseline and other characteristics of the
propensity score-matched patients receiving fondaparinux
or enoxaparin (TKA)
Fondaparinux Enoxaparin P value
n = 204 n = 204
Gender, male/female 30/174 26/178 0.565
Age, years
Mean ± SD 73.6 ± 7.6 73.2 ± 7.7 0.734
Range 34-87 45-89
Body mass index, kg/m2
Mean ± SD 25.4 ± 4.0 25.5 ± 4.0 0.729
History of venous thrombosis,
n (%)
3 (1.5%) 2 (1.0%) 0.500
Comorbidities, n (%)
Hypertension 113 (55.4%) 98 (48.0%) 0.137
Ischemic heart disease 9 (4.4%) 11 (5.4%) 0.647
Diabetes 29 (14.2%) 27 (13.2%) 0.774
Cerebrovascular disease 11 (5.4%) 7 (3.4%) 0.335
Operation time, minutes
Mean ± SD 131.4 ± 41.7 130.2 ± 46.7 0.786
Primary diseases, n (%)
Rheumatoid arthritis 41 (20.1%) 27 (13.2%) 0.063
Osteoarthritis 161 (78.9%) 176 (86.3%) 0.050
Others 2 (1.0%) 1 (0.5%) 0.500
General anesthesia 175 (85.8%) 150 (73.5%) 0.002
Use of elastic stocking, n (%) 195 (95.6%) 184 (90.2%) 0.034
Use of foot pump, n (%) 184 (90.2%) 156 (76.5%) <0.0001
Use of tourniquet, n (%) 187 (91.7%) 193 (94.6%) 0.240
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been studied in patients undergoing TKA [27]. Despite
showing that mechanical prophylaxis significantly reduced
thrombus formation, these studies were low-powered
[28,29], indicating the need for large multicenter random-
ized trials to determine the efficacy of these devices. No
consensus has yet been reached on the anesthetic technique
optimal for thromboprophylaxis in patients undergoingTable 8 Multivariate logistic regression for the composite
effectiveness outcomes (symptomatic/non-symptomatic DVT
up to POD10 and PE up to POD28) in patients receiving THA
Predictors Odds ratio 95% CI P value
Age, ≧75 years 1.82 1.15-2.87 0.011
Female gender 2.31 1.03-5.18 0.041
e-GFR, <60 mL/min per 1.73 m2 0.81 0.44-1.50 0.502
Body mass index, ≧30 kg/m2 0.89 0.36-2.20 0.803
General anesthesia 0.41 0.23-0.71 0.002
Operation time, ≧120 minutes 0.79 0.50-1.23 0.293
Use of foot pump 1.08 0.59-1.96 0.808
Use of elastic stocking 0.51 0.26-1.01 0.052
Medications
Unfractionated heparin 1.27 0.44-3.61 0.658
Enoxaparin 0.84 0.44-1.57 0.577
Fondaparinux 0.36 0.20-0.66 0.001
Others 1.36 0.55-3.36 0.502
CI, confidence interval; DVT, deep vein thrombosis; e-GFR, estimated glomerular
filtrating ratio; PE, pulmonary embolism; THA, total hip arthroplasty.
Use of cement, n (%) 198 (97.1%) 198 (97.1%) 1.000
e-GFR, mL/min per 1.73 m2
Mean ± SD 74.7 ± 22.1 74.2 ± 19.4 0.961
Range 24.1-158.7 30.9-147.5
Serum albumin, g/dL
Mean ± SD 4.0 ± 0.5 4.1 ± 0.4 0.041
Range 2.3-5.0 2.8-4.9
Platelet count, 104/μL
Mean ± SD 24.8 ± 6.9 24.9 ± 7.2 0.913
Kruskal-Wallis rank test were performed on the means of continuous variables. For
categorical variables, chi-squared tests were used. e-GFR, estimated glomerular
filtrating ratio; SD, standard deviation; TKA, total knee arthroplasty.joint replacement. In contrast to previous results [30], we
found that general anesthesia was associated with a reduced
risk for VTE. Studies comparing the incidence of DVT
in patients undergoing general and epidural anesthesia
have yielded contradictory results [31,32]. Moreover,
since about half of our patients received both general
and local anesthesia, further studies are needed.
Although clinical trials have compared the efficacy and
safety of fondaparinux and enoxaparin for preventing
Table 10 Baseline and other characteristics of the
propensity score-matched patients receiving fondaparinux
or enoxaparin (THA)
Fondaparinux Enoxaparin P value
n = 144 n = 144
Gender, male/female 20/124 23/121 0.620
Age, years
Mean ± SD 67.3 ± 10.0 68.0 ± 8.8 0.707
Range 40-87 44-86
Body mass index, kg/m2
Mean ± SD 23.4 ± 3.8 23.8 ± 3.6 0.386
History of venous thrombosis,
n (%)
- -
malignant tumor 5 (3.5%) 0 0.030
Comorbidities, n (%)
Hypertension 59 (41.0%) 54 (37.5%) 0.546
Ischemic heart disease 7 (4.9%) 6 (4.2%) 0.777
Diabetes 11 (7.6%) 10 (6.9%) 0.821
Cerebrovascular disease 4 (2.8%) 3 (2.1%) 0.702
Operation time, minutes
Mean ± SD 124.6 ± 38.7 125.6 ± 47.3 0.931
Primary diseases, n (%)
Rheumatoid arthritis 9 (6.3%) 5 (3.5%) 0.273
Osteoarthritis 129 (89.6%) 129 (89.6%) 1.000
Others 6 (4.2%) 10 (6.9%) 0.303
General anesthesia 141 (97.9%) 141 (97.9%) 1.000
Use of elastic stocking, n (%) 131 (91.0%) 133 (92.4%) 0.670
Use of foot pump, n (%) 138 (95.8%) 137 (95.1%) 0.777
Use of cement, n (%) 23 (16.0%) 24 (16.7%) 0.873
e-GFR, mL/min per 1.73 m2
Mean ± SD 81.9 ± 20.0 78.6 ± 16.8 0.220
Range 29.0-139.0 37.7-128.9
Serum albumin, g/dL
Mean ± SD 4.0 ± 0.5 4.1 ± 0.4 0.001
Range 2.4-5.0 2.6-5.1
Platelet count, 104/μL
Mean ± SD 27.7 ± 7.6 26.0 ± 7.7 0.048
Kruskal-Wallis rank test were performed on the means of continuous variables.
For categorical variables, chi-squared tests were used. e-GFR, estimated
glomerular filtrating ratio; SD, standard deviation; THA, total hip arthroplasty.
Table 11 Incidences of any DVT (up to POD10) and major
bleeding (up to POD28) in propensity-matched
fondaparinux- or enoxaparin-treated groups (TKA)
Events Fondaparinux Enoxaparin Risk ratio
(95% CI)
P value
n = 204 n = 204
DVT 28/204 (13.6%) 54/204 (26.2%) 0.70 (0.58-0.85) 0.002
Major
bleeding
7/204 (3.4%) 1/204 (0.5%) 4.18 (0.67-26.20) 0.062
CI, confidence interval; DVT, deep vein thrombosis; POD, postoperative day;
TKA, total knee arthroplasty.
Table 12 Incidences of any DVT (up to POD10) and major
bleeding (up to POD28) in propensity-matched
fondaparinux- or enoxaparin-treated groups (THA)
Events Fondaparinux Enoxaparin Risk ratio
(95% CI)
P
valuen = 144 n = 144
DVT 8/144 (5.6%) 16/144 (11.1%) 0.73 (0.53-0.99) 0.134
Major bleeding 7/144 (4.9%) 0/144 (0%) - 0.022
CI, confidence interval; DVT, deep vein thrombosis; POD, postoperative day;
THA, total hip arthroplasty.
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the lower limbs [33-36], these two agents were never
compared directly in Japanese patients. When we com-
pared their effectiveness in a propensity score-matched
population, we found that fondaparinux significantly re-
duced the incidence of ultrasound-proven DVT compared
with enoxaparin. In contrast, major bleeding, leading to a
requirement for transfusion of at least one unit of blood
or occurring in a critical organ, occurred more frequentlyin the fondaparinux- than in the enoxaparin-treated
group. A meta-analysis of four randomized double-blind
trials comparing fondaparinux with enoxaparin found that
2.5 mg/day fondaparinux was superior to approved enoxa-
parin regimens in preventing VTE [37]. Furthermore, the
overall incidence of clinical-relevant bleeding did not
differ between the two groups, and the benefit of fon-
daparinux was consistent across all studies. In one trial,
however, the rates of major bleeding were significantly
higher with fondaparinux than with enoxaparin [36]. The
lack of consistency in defining “bleeding” in these studies,
including ours, creates difficulties in interpreting the
true benefit-harm balance. Pharmacological prophylaxis in
patients undergoing major orthopedic surgery is of con-
cern because of the increased risk of bleeding. Several
previous studies have found an interaction between dose
of fondaparinux and risk of major bleeding [38,39]. Over-
all, clinicians must make trade-offs between the benefits
of reducing thrombosis and adverse effects, including
bleeding, when using fondaparinux in Japanese patients.
Some methodological aspects and possible limitations
of this study require comment. First, because of the non-
interventional, open-label study design and limitations
inherent to observational studies, the estimated risks were
not unbiased. Owing to a lack of randomization, observa-
tional studies are confounded by indication. Although our
study cohort was large and the study population was
adjusted for a large number of confounding covariates, we
could not adjust for all confounders. Thus, this obser-
vational study was not the equivalent of a randomized
control trial. Second, indications for thromboprophylaxis
varied widely among physicians and within hospitals,
introducing an inherent selection bias. The incorporation
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this study may be questionable [9]. However, DVT, both
symptomatic and non-symptomatic, has been linked with
symptomatic or fatal PE [40]. Venography is generally
accepted as the gold standard in detecting DVT. A recent
systematic review suggested that ultrasound is accurate
for the postoperative diagnosis of DVT in asymptomatic
orthopedic patients [13]. Additionally, the use of blinded
investigators and independent adjudication may reduce
some of the imprecision stemming from subjectivity and
variability among observers [41]. Although the risk of
VTE was shown to be extended by periods beyond the
usual periods of hospitalization [42], the duration of
pharmacological prophylaxis was relatively limited in our
study. The association between mortality and major bleed-
ing is strong in the first 30 days; however, it remains sig-
nificant up to 3 years [43]. Our study did not determine
whether in-hospital bleeding affects the long-term out-
comes. Most asymptomatic DVTs detected by using the
CUS method were distal, for which the diagnostic per-
formance of CUS is poorer than for proximal DVT [44].
However, CUS yielded much better diagnostic perform-
ance in patients with asymptomatic DVT when performed
by staff with substantial experience in ultrasonography
and when a standardized examination procedure was used
[45], as in our study. Even if the relative inaccuracy of
CUS for detecting distal DVTs was real in our study, it
would not explain the decreased incidences of DVT in
patients receiving a certain thromboprophylaxis agent,
because the same diagnostic procedure was used in
all patients, regardless of thromboprophylactic agent.
Propensity scores are estimated by using a large number
of measured pretreatment covariates in a multivariate
logistic regression model to predict exposure. Thus, pro-
pensity score-matched analysis of patients receiving fon-
daparinux and enoxaparin mimics a randomized trial.
However, unmeasured characteristics and confounders are
not completely balanced.
Our study represents the most comprehensive, hos-
pital-based cohort study to date, with the outcomes in
all enrolled patients completely followed. The partici-
pants in this study, in contrast to those in many clinical
trials, were similar demographically to the general popu-
lation undergoing joint replacement, suggesting that our
findings are applicable to the general population. The
J-PSVT has been able to recruit a large, diverse popula-
tion of patients undergoing THA or TKA and therefore
was able to identify factors affecting outcomes that may
not be apparent in clinical trials.
Conclusions
This large, prospective, multicenter analysis assessed
VTE risks and bleeding in patients undergoing joint
replacement surgery under conditions reflecting routine“real-world” clinical practice in Japan. Our results sug-
gest that fondaparinux prophylaxis can reduce DVT but
that it is accompanied by a high risk of bleeding. These
gaps between recommendations and real-world outcomes
should be addressed by additional prospective studies or
the registry.
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